Mesa Laboratories Financials
MLAB Stock | USD 100.86 2.27 2.30% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 1.6 | 1.5248 |
|
| |||||
Current Ratio | 2.34 | 2.4678 |
|
|
The financial analysis of Mesa Laboratories is a critical element in measuring its lifeblood. Investors should not minimize Mesa Laboratories' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Mesa | Select Account or Indicator |
Understanding current and past Mesa Laboratories Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mesa Laboratories' financial statements are interrelated, with each one affecting the others. For example, an increase in Mesa Laboratories' assets may result in an increase in income on the income statement.
Mesa Laboratories Earnings Geography
Please note, the presentation of Mesa Laboratories' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mesa Laboratories' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mesa Laboratories' management manipulating its earnings.
Mesa Laboratories Stock Summary
Mesa Laboratories competes with Novanta, Itron, Fortive Corp, Vishay Precision, and Coherent. Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Mesa Labs operates under Scientific Technical Instruments classification in the United States and is traded on NASDAQ Exchange. It employs 681 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US59064R1095 |
CUSIP | 59064R109 |
Location | Colorado; U.S.A |
Business Address | 12100 West Sixth |
Sector | Life Sciences Tools & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.mesalabs.com |
Phone | 303 987 8000 |
Currency | USD - US Dollar |
Mesa Laboratories Key Financial Ratios
Return On Equity | -0.89 | ||||
Profit Margin | (1.08) % | ||||
Operating Margin | 0.07 % | ||||
Price To Sales | 2.34 X | ||||
Revenue | 216.19 M |
Mesa Laboratories Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 420.2M | 600.2M | 707.4M | 661.8M | 446.8M | 469.1M | |
Other Current Liab | 14.7M | 9.9M | 14.8M | 20.0M | 18.2M | 19.1M | |
Net Debt | 60.0M | (117.2M) | 171.8M | 137.4M | 203.1M | 213.2M | |
Retained Earnings | 71.9M | 72.5M | 76.7M | 74.2M | (183.5M) | (174.3M) | |
Cash | 81.4M | 263.9M | 49.3M | 32.9M | 28.2M | 17.3M | |
Other Assets | 11.5M | 275.1M | 554.4M | 2.8M | 1.0 | 0.95 | |
Net Receivables | 21.1M | 23.8M | 41.2M | 42.6M | 39.1M | 41.0M | |
Inventory | 14.2M | 11.2M | 24.6M | 34.6M | 32.7M | 34.3M | |
Total Liab | 200.2M | 193.9M | 313.6M | 268.4M | 301.4M | 316.5M | |
Total Current Assets | 122.8M | 303.0M | 124.3M | 119.0M | 109.4M | 114.8M | |
Other Current Assets | 41.4M | 4.9M | 9.1M | 86.1M | 9.4M | 10.2M | |
Accounts Payable | 3.4M | 4.5M | 7.9M | 6.1M | 6.0M | 6.3M | |
Short Term Debt | 1.1M | 14.8M | 6.9M | 2.9M | 3.0M | 4.5M | |
Intangible Assets | 119.9M | 111.7M | 250.1M | 18.2M | 113.8M | 119.4M | |
Common Stock | 158.0M | 317.7M | 313.5M | 332.1M | 343.6M | 360.8M | |
Good Will | 141.5M | 160.8M | 291.2M | 286.4M | 180.1M | 189.1M | |
Long Term Debt | 140.3M | 145.7M | 218.4M | 183.3M | 221.7M | 232.8M | |
Net Tangible Assets | (41.4M) | 294.5M | 393.8M | 107.0M | 123.1M | 101.8M | |
Other Liab | 32.6M | 193.9M | 39.7M | 36.0M | 41.4M | 32.9M | |
Long Term Debt Total | 20.6M | 140.3M | 145.7M | 183.3M | 210.8M | 221.3M |
Mesa Laboratories Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 5.5M | 8.0M | 3.9M | 3.7M | 5.7M | 6.0M | |
Total Revenue | 117.7M | 133.9M | 184.3M | 219.1M | 216.2M | 227.0M | |
Gross Profit | 64.9M | 87.0M | 109.1M | 133.7M | 133.3M | 139.9M | |
Cost Of Revenue | 52.8M | 46.9M | 75.2M | 85.4M | 82.9M | 87.1M | |
Operating Income | (4.9M) | (5.3M) | (20.4M) | (30.5M) | (272.1M) | (258.5M) | |
Ebit | (4.9M) | (5.1M) | 4.7M | 3.3M | (270.0M) | (256.5M) | |
Ebitda | 8.1M | 12.4M | 29.8M | 36.5M | (238.4M) | (226.5M) | |
Income Before Tax | 3.4M | 2.3M | 3.6M | (389K) | (275.6M) | (261.9M) | |
Net Income | 1.3M | 3.3M | 1.9M | 930K | (254.2M) | (241.5M) | |
Income Tax Expense | 2.1M | (971K) | 1.7M | (1.3M) | (21.4M) | (20.3M) | |
Research Development | 6.4M | 10.4M | 15.8M | 20.5M | 19.3M | 20.3M | |
Tax Provision | 2.1M | (971K) | 1.7M | (1.3M) | (21.4M) | (20.3M) |
Mesa Laboratories Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 414K | 929K | (1.0M) | (10.2M) | 2.6M | 2.7M | |
Change In Cash | 71.2M | 182.5M | (214.5M) | (16.4M) | (4.7M) | (4.5M) | |
Free Cash Flow | 25.1M | 35.1M | 34.8M | 23.4M | 41.6M | 43.6M | |
Depreciation | 13.0M | 17.7M | 25.1M | 33.8M | 31.6M | 33.2M | |
Other Non Cash Items | 11.8M | 5.1M | 8.0M | 1.3M | 277.3M | 291.2M | |
Capital Expenditures | 1.5M | 2.0M | 4.4M | 4.5M | 2.6M | 1.8M | |
Net Income | 1.3M | 3.3M | 1.9M | 930K | (254.2M) | (241.5M) | |
End Period Cash Flow | 81.4M | 263.9M | 49.3M | 32.9M | 28.2M | 18.0M | |
Dividends Paid | 2.7M | 3.2M | 3.3M | 3.4M | 3.4M | 2.3M | |
Change Receivables | 1.6M | (1.7M) | (647K) | (2.1M) | (1.9M) | (1.8M) | |
Net Borrowings | 144.1M | (664K) | 49M | (36M) | (41.4M) | (39.3M) | |
Change To Netincome | 6.9M | 11.3M | 19.5M | 10.3M | 11.9M | 12.5M | |
Investments | (185.6M) | (2.0M) | (305.2M) | (9.5M) | (81.3M) | (85.4M) |
Mesa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mesa Laboratories's current stock value. Our valuation model uses many indicators to compare Mesa Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mesa Laboratories competition to find correlations between indicators driving Mesa Laboratories's intrinsic value. More Info.Mesa Laboratories is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At present, Mesa Laboratories' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesa Laboratories' earnings, one of the primary drivers of an investment's value.Mesa Laboratories' Earnings Breakdown by Geography
Mesa Laboratories Systematic Risk
Mesa Laboratories' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mesa Laboratories volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Mesa Laboratories correlated with the market. If Beta is less than 0 Mesa Laboratories generally moves in the opposite direction as compared to the market. If Mesa Laboratories Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mesa Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mesa Laboratories is generally in the same direction as the market. If Beta > 1 Mesa Laboratories moves generally in the same direction as, but more than the movement of the benchmark.
Mesa Laboratories Thematic Clasifications
Mesa Laboratories is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Measuring and Control Equipment | View |
Today, most investors in Mesa Laboratories Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mesa Laboratories' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mesa Laboratories growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Mesa Laboratories November 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mesa Laboratories help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mesa Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mesa Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing Mesa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mesa Laboratories's daily price indicators and compare them against related drivers.
Information Ratio | (0.13) | |||
Maximum Drawdown | 23.18 | |||
Value At Risk | (5.50) | |||
Potential Upside | 3.41 |
Complementary Tools for Mesa Stock analysis
When running Mesa Laboratories' price analysis, check to measure Mesa Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesa Laboratories is operating at the current time. Most of Mesa Laboratories' value examination focuses on studying past and present price action to predict the probability of Mesa Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesa Laboratories' price. Additionally, you may evaluate how the addition of Mesa Laboratories to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |